This phase 2 study was designed to evaluate the efficacy of mobocertinib 160 mg QD in Japanese patients with locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations and who had not previously received systemic treatment for locally advanced or metastatic disease. This evidence concerns the gene EGFR and non-small cell lung carcinoma.